Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs.

Pedicino, Daniela; Volpe, Massimo

A recent study published in the European Heart Journal examined the efficacy and safety of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM). The study involved 616 participants who were randomly assigned to receive semaglutide or a placebo for 52 weeks. The results showed that semaglutide significantly improved HF-related symptoms, physical limitations, and quality of life compared to the placebo. Additionally, semaglutide led to greater weight loss and a reduction in heart failure events. However, the study had limitations, such as soft endpoints and a short-term follow-up. Further research is needed to confirm these findings and assess the effects of semaglutide on clinical events.

TYPE 2 diabetes; TREATMENT effectiveness; DRUG dosage; PEOPLE with diabetes; PLACEBOS; HEART failure

European Heart Journal, 2024, Vol 45, Issue 37, p3787

0195-668X

Academic Journal

10.1093/eurheartj/ehae427